Tracer Biotechnologies is pleased to announce a strategic partnership with Qiagen (QGEN) to co-develop and commercialize minimal residual disease assays for solid tumors on Qiagen’s QIAcuity digital PCR platform. This collaboration aims to deliver highly sensitive, cost-effective, and decentralized MRD testing solutions that enable oncologists to monitor cancer recurrence and guide personalized treatment decisions using minimally invasive blood samples.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QGEN:
- Qiagen N.V. Reports Significant Voting Rights Held by BlackRock
- Qiagen announces strategic partnership with Foresight Diagnostics
- Qiagen expands digital PCR oncology research portfolio
- Citi opens ‘upside 90-day short-term view’ on Qiagen
- Cautious Optimism for Qiagen Amidst Industry Challenges: Awaiting Long-term Growth Assurance